Please login to the form below

Not currently logged in
Email:
Password:

J&J appoints Bayer’s Sandra Peterson as group worldwide chair

Will have responsibility for troubled consumer goods division

J&J - Sandra PetersonSandra Peterson is to leave her role as chair and CEO of Bayer CropScience to join Johnson & Johnson (J&J) as its group worldwide chair.

Joining J&J on December 1, 2012, Peterson will have responsibility for J&J's IT and global supply chain, as well as its troubled consumer division, which has been beset by recalls and quality control problems these past two years.

The appointment is the first major executive change at J&J since Alex Gorsky became CEO in April, 2012, and he gave his thoughts on what Peterson could bring to such a high profile role.

“Sandi Peterson is an experienced global leader known for her strategic thinking and proven track record in growing businesses,” he said.

“She brings 25 years of experience to her new role, which will draw on her expertise in building fully integrated global businesses, and focusing on growth.”

Peterson has held her current role at Bayer since 2010, having previously served as president and CEO of Bayer Medical Care and president of Bayer HealthCare AG's Diabetes Care Division.

Prior to joining Bayer in 2005, Peterson spent five years in leadership roles at Medco Health Solutions following a series of positions at Nabisco, Whirlpool Corporation and McKinsey & Company.

“With her experience and commitment, Sandi has made significant contributions to the strong business performance of Bayer CropScience in the past two years,” said Dr Marijn Dekkers, CEO of Bayer.

“However, we accept her decision to continue her career back in her home country of the US and wish her all the best for the future.”

18th September 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...